The Latin America pharmaceutical contract manufacturing and research services market size stood at US$ 22.53 billion in 2025, grew to US$ 24.09 billion in 2026, and is forecast to reach US$ 43.99 billion by 2035, expanding at a CAGR of 6.92% from 2026 to 2035. With growing demand for novel and complex therapeutics, CMOs and CDMOs play an important role in meeting healthcare needs, which increases the demand for the market.
Contract manufacturing organizations (CMOs) are entities that produce products on behalf of other companies. A CMO primarily specializes in manufacturing drugs according to the client's formula, ensuring smooth, efficient, and regulation-compliant processes. Outsourcing production reduces financial risks and speeds up market entry by utilizing specialized equipment and expertise. These firms mainly focus on pharmaceutical production and offer a variety of services, including formulation, testing, research and development, and packaging.
Automation is renovating the traditional strategies used to develop, produce, and deliver APIs, from intelligent technology optimization to predictive maintenance. AI-based algorithms address challenges posed by data in manufacturing practices by determining where improvements can be made and even changing an operational procedure in a real-time environment. AI enhances R&D processes by analysing molecular data to aid in the identification of compounds additional probable to be successful. Automation platforms rapidly reprogrammed for the novel API or the latest formulation. This flexibility enables contract manufacturing consultants to rapidly adapt to consumer requests for various types of products, from small biochemical batches for clinical trials to massive production. Integration with the automation of production lines, novel APIs produced from the laboratory setting, and commercialization in the limited time frame possible.
By service type, the contract manufacturing services (CMO) segment contributed the largest Latin America pharmaceutical contract manufacturing and research services market share of 65% in 2025. Contract manufacturing supports international businesses in getting their product mass-produced or assembled at reduced expenses. With the support of contract manufacturing, international organizations are allowed to produce their goods on a large scale without spending on setting up manufacturing services.
By product type, the small molecule drugs segment contributed the largest market share of 58%, as small molecule drugs offer various benefits, starting with their increasing oral bioavailability, which enables convenient self-administration, most often in oral solid dose (OSD) form. This encourages patient compliance, making them suitable for the long-term treatment of long-lasting conditions. Small molecules are often more affordable for production.
By Therapeutic Area, the oncology segment held a significant share of 28% in the Latin America pharmaceutical contract manufacturing and research services market. Drugs manufactured by CMOs have been shown to receive approval up to 30% faster than those developed and produced in-house by smaller pharma organizations. CMOs allow flexible manufacturing schedules and volume adjustments based on demand, which is significant to the often-variable requirements of oncology drug manufacturing.
By end user, the pharmaceutical companies segment contributed the largest market share of 48%, which provides benefits such as shorter product lead times, growing flexibility, and advanced regulatory compliance. Third-party manufacturing offers flexibility and scalability to pharmaceutical organizations, enabling them to adapt to variations.
Leading companies in the Latin America Pharmaceutical Contract Manufacturing and Research Services Market include Boehringer Ingelheim, Lonza, Thermo Fisher Scientific, and IQVIA. Meanwhile, Boehringer Ingelheim is providing inclusive contract manufacturing for biopharmaceuticals, and Lonza specializes in advanced biologics and cell and gene therapies, supporting partners from initial research. Thermo Fisher offers end-to-end contract development and manufacturing organization (CDMO) and clinical research services, and IQVIA is working expansively through the region to manage clinical trials and data analytics.
By Service Type
By Product Type
By Therapeutic Area
By End User
By Region
